To include your compound in the COVID-19 Resource Center, submit it here.

Quark siRNA meets Phase II kidney injury endpoint

Quark Pharmaceuticals Inc. (Fremont, Calif.) said QPI-1002 met the primary endpoint in a Phase II trial to prevent acute

Read the full 194 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE